HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN. | UCSF Helen Diller Family Comprehensive Cancer Center

Author List

Schmidt G, Gluz O, Christgen M, Reinisch M, Kümmel S, Nitz U, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, Mahlberg R, Malter W, Reimer T, Nuding B, Stefek A, Wuerstlein R, Graeser M, Józwiak K, Burmeister S, Zu Eulenburg C, Lauseker M, Kolberg-Liedtke C, Prat A, Schmid P, Baehner R, Kreipe HH, Solomayer EF, Harbeck N, West German Stud
y Group investigators

Publication

Breast cancer research : BCR

Publication ID (Profile URL)

https://researcherprofiles.org/profile/593758900

Publication Year

2025

PubMed ID

39953511

Publication Title

Schmidt G, Gluz O, Christgen M, Reinisch M, Kümmel S, Nitz U, Braun M, Aktas B, Lüdtke-Heckenkamp K, Forstbauer H, Grischke EM, Schumacher C, Mahlberg R, Malter W, Reimer T, Nuding B, Stefek A, Wuerstlein R, Graeser M, Józwiak K, Burmeister S, Zu Eulenburg C, Lauseker M, Kolberg-Liedtke C, Prat A, Schmid P, Baehner R, Kreipe HH, Solomayer EF, Harbeck N, West German Stud
y Group investigators. HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN. Breast Cancer Res. 2025 Feb 14; 27(1):22.